Pricing

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.

Highlights of last year's ISPOR European Congress panel debated on one of the key issues regarding patient access to transformative treatments: adaptive pathways and the application of real-world evidence.

Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale

Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.

Payers and pharma must shift away from the traditional one drug–one price approach and expand "indication-based pricing", writes Anaïs Frappé.

If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

The significance of real-world data has been not utilized to the full potential, writes Uttam Barick.

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared-including the role of the patient in the equation.

To gain better alignment of coverage and risk, evidence-based arguments are critical during the underwriting process.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

Pharma leaders go on the defensive over drug pricing regulations, while experts slam the politicization of healthcare.

How companies are closing the innovation gap between the lab and the patient, while also creating value for all stakeholders.

Connected ecosystems will change the future of healthcare. Three key value drivers are outlined.

Pharm Exec sits down with AmerisourceBergen supply chain leader Peyton Howell to discuss the latest trends in pharmaceutical distribution, including company efforts to boost efficiency, reliability, and enhance its groundbreaking partnership with Walgreens Boots Alliance.

Jill Wechsler on the need for more efficient methods of documenting treatment benefits in medical practice.

How companies can better integrate valuable data across business functions to meet rising value-chain demands.

There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.

Even though pharma's “dark days” are fading away, the chill of the last few months will not soon be forgotten, writes Tom Norton.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

How a broader “value” understanding can benefit brand teams.

What are the chances that Rx price controls will actually take hold in the U.S. in the near future? Tom Norton believes the answer to that question can summed up in one word: California.

Scale has its limits, as the nation’s two largest pharmacy benefit managers (PBM), Express Scripts and CVS Caremark, are discovering. Stephen Littlejohn reports.